In experiments targeting FGL2 (an immune‐suppressive regulator) for the treatment of gliomas, blocking FGL2 on T cells increased CXCR3 expression on CD8+ TRM, promoted their proliferation, and enhanced granzyme B secretion. Here, CD8A is linked to central nervous system cancer.